Mechanisms of diabetic kidney disease and established and emerging treatments
6.5
来源：
Nature
关键字：
computational pathology
发布时间：
2025-09-11 23:34
摘要：
Diabetic kidney disease (DKD) is a significant complication of diabetes, leading to high mortality rates. The article reviews established treatments such as SGLT2 inhibitors and GLP-1 receptor agonists, which have shown efficacy in slowing disease progression. It also discusses emerging therapies and the underlying mechanisms of DKD, emphasizing the importance of ongoing research to explore new therapeutic targets. The findings from major clinical trials are summarized, providing insights into the evolving treatment landscape for DKD.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
1.0分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
0.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.0分+团队与机构背景
technical_barrier_competition
0.0分+技术壁垒与竞争格局
关键证据
Diabetic kidney disease (DKD) is diagnosed by an estimated glomerular filtration rate <60 ml/min/1.73 m².
Large outcome trials have demonstrated that sodium–glucose cotransporter 2 inhibitors slow chronic kidney disease progression.
Emerging strategies to prevent or halt DKD are highlighted.
真实性检查
否
AI评分总结
Diabetic kidney disease (DKD) is a significant complication of diabetes, leading to high mortality rates. The article reviews established treatments such as SGLT2 inhibitors and GLP-1 receptor agonists, which have shown efficacy in slowing disease progression. It also discusses emerging therapies and the underlying mechanisms of DKD, emphasizing the importance of ongoing research to explore new therapeutic targets. The findings from major clinical trials are summarized, providing insights into the evolving treatment landscape for DKD.